Can a pill keep mantle cell lymphoma away? new study tests ibrutinib maintenance
NCT ID NCT02242097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free and what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ibrutinib
- What this could lead to
- If it works, this could offer a way to keep mantle cell lymphoma from coming back longer after initial treatment.
- What could go wrong
- This is a small, early-phase study (37 people) with no comparison group, so results may not be definitive. Ibrutinib can cause side effects like bleeding, infection, or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Northwestern University- Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
University of Utah
Salt Lake City, Utah, 84132, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.